Low expression of tRF-Pro-CGG predicts poor prognosis in pancreatic ductal adenocarcinoma.
Adenocarcinoma
/ diagnosis
Base Sequence
Carcinoma, Pancreatic Ductal
/ diagnosis
Disease-Free Survival
Down-Regulation
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Multivariate Analysis
Neoplasm Staging
Pancreatic Neoplasms
/ diagnosis
Prognosis
RNA, Transfer
/ genetics
ROC Curve
Pancreatic Neoplasms
fluorescence in situ hybridization
pancreatic ductal adenocarcinoma
tRF-Pro-CGG
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
29
01
2021
received:
04
01
2021
accepted:
10
02
2021
pubmed:
7
3
2021
medline:
24
11
2021
entrez:
6
3
2021
Statut:
ppublish
Résumé
tRFs (tRNA-derived RNA fragments) have been reported to facilitate cancer progression in multiple cancers. However, their role in pancreatic ductal adenocarcinoma (PDAC) remains to be determined. In this study, we mainly investigated the expression of tRF-Pro-CGG in pancreatic ductal adenocarcinoma and evaluated its relationship with the clinicopathology and survival time of patients. 37 cases of pancreatic ductal adenocarcinoma, and 15 cases of normal pancreatic tissues were collected which were resected by surgery from January 2017 to June 2020 from the Department of Hepatobiliary and Pancreatic surgery of Changzhou second people's Hospital. The expression of tRF-Pro-CGG in paraffin-embedded tissues was detected by fluorescence in situ hybridization (FISH). The clinical data including age, sex, tumor location, tumor diameter, tumor clinical stage (TNM stage), depth of invasion, regional lymph node metastasis, serum CA199, and serum CEA were collected and analyzed retrospectively, whether the expression tRF-Pro-CGG was correlation with the pathological parameters and clinical outcomes of patients. The expression level of tRF-Pro-CGG was significantly downregulated in PDAC and associated with an advanced TNM stage (P=0.000) and the N stage (P=0.000) of patients. More importantly, low tRF-Pro-CGG expression predicted poor survival in PDAC patients (P=0.003). TRF-Pro-CGG is under-expressed in PDAC and is associated with short clinical survival and poor prognosis. tRF-Pro-CGG is an independent prognostic factor, which highlights its role as a potential biomarker for PDAC progression and therapy.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
tRFs (tRNA-derived RNA fragments) have been reported to facilitate cancer progression in multiple cancers. However, their role in pancreatic ductal adenocarcinoma (PDAC) remains to be determined. In this study, we mainly investigated the expression of tRF-Pro-CGG in pancreatic ductal adenocarcinoma and evaluated its relationship with the clinicopathology and survival time of patients.
METHODS
METHODS
37 cases of pancreatic ductal adenocarcinoma, and 15 cases of normal pancreatic tissues were collected which were resected by surgery from January 2017 to June 2020 from the Department of Hepatobiliary and Pancreatic surgery of Changzhou second people's Hospital. The expression of tRF-Pro-CGG in paraffin-embedded tissues was detected by fluorescence in situ hybridization (FISH). The clinical data including age, sex, tumor location, tumor diameter, tumor clinical stage (TNM stage), depth of invasion, regional lymph node metastasis, serum CA199, and serum CEA were collected and analyzed retrospectively, whether the expression tRF-Pro-CGG was correlation with the pathological parameters and clinical outcomes of patients.
RESULTS
RESULTS
The expression level of tRF-Pro-CGG was significantly downregulated in PDAC and associated with an advanced TNM stage (P=0.000) and the N stage (P=0.000) of patients. More importantly, low tRF-Pro-CGG expression predicted poor survival in PDAC patients (P=0.003).
CONCLUSIONS
CONCLUSIONS
TRF-Pro-CGG is under-expressed in PDAC and is associated with short clinical survival and poor prognosis. tRF-Pro-CGG is an independent prognostic factor, which highlights its role as a potential biomarker for PDAC progression and therapy.
Identifiants
pubmed: 33675071
doi: 10.1002/jcla.23742
pmc: PMC8128309
doi:
Substances chimiques
RNA, Transfer
9014-25-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23742Subventions
Organisme : Major Science and Technology Program of Changzhou Health Commission in 2020
ID : ZD202023
Organisme : Changzhou Medical Innovation Team Project
ID : CCX201807
Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
JAMA. 2013 Oct 9;310(14):1473-81
pubmed: 24104372
Cancer Lett. 2019 Jun 28;452:31-37
pubmed: 30905816
Genes Dev. 2010 Dec 15;24(24):2742-7
pubmed: 21106669
Science. 2016 Jan 22;351(6271):397-400
pubmed: 26721680
Oncol Lett. 2019 Sep;18(3):3104-3114
pubmed: 31452788
Cancer Biol Ther. 2010 May 15;9(10):754-63
pubmed: 20234186
J Gen Virol. 2017 Jul;98(7):1600-1610
pubmed: 28708049
Ann Surg. 2003 Jan;237(1):74-85
pubmed: 12496533
Clin Lab. 2020 Jun 1;66(6):
pubmed: 32538051
Mol Cancer. 2019 Apr 2;18(1):74
pubmed: 30940133
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
J Am Coll Surg. 1999 Jul;189(1):1-7
pubmed: 10401733
Nucleic Acids Res. 2014 Jun;42(11):7290-304
pubmed: 24838567
Cell. 2015 May 7;161(4):790-802
pubmed: 25957686
Nucleic Acids Res. 2009 Oct;37(19):6575-86
pubmed: 19729508
FEBS Lett. 2009 Jan 22;583(2):437-42
pubmed: 19114040
Onco Targets Ther. 2020 Oct 28;13:10931-10943
pubmed: 33149609
Genes (Basel). 2018 May 10;9(5):
pubmed: 29748504
Int J Cancer. 2019 Sep 1;145(5):1395-1407
pubmed: 30828790
Science. 2016 Jan 22;351(6271):391-396
pubmed: 26721685
Cancer Biomark. 2019;25(2):169-176
pubmed: 31104009
Cancer. 2011 May 15;117(10):2044-9
pubmed: 21523715
J Mol Med (Berl). 2018 Nov;96(11):1167-1176
pubmed: 30232504
J Biol Chem. 2010 Apr 2;285(14):10959-68
pubmed: 20129916
Nature. 2017 Dec 7;552(7683):57-62
pubmed: 29186115
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Ann Oncol. 2014 Aug;25(8):1650-6
pubmed: 24759568
Cell. 2017 Jun 29;170(1):61-71.e11
pubmed: 28666125
Mol Ther. 2013 Feb;21(2):368-79
pubmed: 23183536
Nature. 2013 Mar 28;495(7442):474-80
pubmed: 23474986
Arch Biochem Biophys. 2020 Sep 15;690:108467
pubmed: 32592804
J Biol Chem. 2006 Dec 29;281(52):40440-9
pubmed: 17082189
RNA. 2018 Aug;24(8):1093-1105
pubmed: 29844106
Mol Cell. 2011 Aug 19;43(4):613-23
pubmed: 21855800
Dig Dis. 2004;22(1):26-31
pubmed: 15292692
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1404-9
pubmed: 23297232
Oncol Rep. 2007 Jul;18(1):151-5
pubmed: 17549361
Chem Biol Drug Des. 2017 Nov;90(5):730-738
pubmed: 28378898
RNA Biol. 2013 Apr;10(4):553-63
pubmed: 23563448
Hum Mutat. 2016 Dec;37(12):1283-1298
pubmed: 27516218
Onco Targets Ther. 2019 Aug 16;12:6371-6383
pubmed: 31496739
RNA. 2010 Apr;16(4):673-95
pubmed: 20181738
Genes Dev. 2009 Nov 15;23(22):2639-49
pubmed: 19933153